ViewsML
PrivateLast Round
Seed
Apr 20, 2026
Total Funding Raised
$3.58M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
ViewsML operates in Healthcare & Life Sciences and is based in Vancouver. Its latest recorded funding round was a Seed round in April 2026.
ViewsML is a healthcare IT company that has developed an AI-powered platform and virtual biomarker library to generate per-cell biomarker spatial insights from standard pathology images, eliminating the need for physical laboratory staining.
Sector
Healthcare & Life Sciences
Verticals
Medical AI, Medical Imaging, Drug Discovery, Precision Medicine, Computer Vision
Business Model
B2B
Customer Profile
Subscription SaaS, Usage-Based SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ViewsML Comparables
Compare ViewsML with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pictor Labs | 89% | |
| Acurion | 83% | |
| ITsci Company Limited | 77% |
For institutional investors. Book with your work email.
ViewsML Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ViewsML Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| WUTIF Management Corporation | Seed |
| Defined | Seed |
| RiSC Capital | Seed |
| Wittington Ventures | Seed |
| Defined | Seed |
| Continuum Health Ventures | Seed |
| SFU VentureLabs | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 998% MoM, reaching 5.2K.
- Jul 20, 2026
Open roles increased to 4, 2.7x the trailing average.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 30, 2026
ViewsML appointed Digital Pathology executive Michael Rivers to its Board of Directors in Canada on Sep 29th '26.
- is_developingSep 30, 2026
ViewsML is developing the world's first virtual biomarker library to enable scientists and clinicians to perform virtual staining in minutes instead of the days to weeks required by traditional laboratory methods.
For institutional investors. Book with your work email.
ViewsML Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ViewsML's valuation, stock price, and market status.
Is ViewsML a public or private company?
ViewsML is a private company.
What is the current stock price of ViewsML?
ViewsML is a private company, so its shares have no public market price. Caplight tracks ViewsML's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ViewsML worth (valuation)?
Valuation information for ViewsML is not publicly available.
Can I buy ViewsML stock?
ViewsML shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ViewsML's last funding round?
ViewsML's most recent funding round was Seed on April 20, 2026.
Who are the main investors in ViewsML?
Key investors in ViewsML include Wittington Ventures.
Will ViewsML IPO soon?
No public IPO plans have been announced for ViewsML.
How can I track ViewsML secondary market activity?
Caplight tracks bids, offers, and trades in ViewsML's shares on secondary markets.